Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The global epidemic of obesity and the metabolic syndrome has focused the need for novel treatments. Here we describe the putative pathogenic role of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), an enzyme that generates active glucocorticoid, cortisol, within liver and adipose tissue. Furthermore, we review the published literature on the development of selective 11β-HSD1 inhibitors as a therapeutic strategy in light of their emerging role as insulin sensitisers. © 2005 Elsevier Ltd. All rights reserved.

Original publication




Journal article


Drug Discovery Today: Therapeutic Strategies

Publication Date





93 - 96